Regenicin, Inc.

Equities

RGIN

US75887Q1022

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 13:26:13 2024-05-13 EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2023	Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI
2023	Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	CI

Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021

January 13, 2022 at 10:03 am

Regenicin, Inc. reported earnings results for the full year ended September 30, 2021. For the full year, the company reported net loss was USD 0.877102 million compared to USD 0.559591 million a year ago. Basic loss per share from continuing operations was USD 0.01.

Diluted loss per share from continuing operations was USD 0.01.

Latest news about Regenicin, Inc.

Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-13	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-13	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-12	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-23	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-14	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	22-01-13	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-23	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-17	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-13	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-19	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	20-05-20	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019	20-02-19	CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019	20-01-14	CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019	19-08-19	CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2019	19-05-20	CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2018	19-02-19	CI
Regenicin, Inc. Announces Resignation of Craig Eagle from the Board of Directors	17-08-08	CI
Regenicin Inc. Announces Demise of Joseph Rubinfeld, Member of Board of Directors	17-01-03	CI
Regenicin Inc. Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm	16-11-17	CI
Regenicin Completes Pre-IND Meeting with Food and Drug Administration for its New Autologous Cultured Skin Substitute, NovaDerm	16-11-01	CI
U.S. Food and Drug Administration Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute	16-08-29	CI
Regenicin, Inc. Auditor Raises 'Going Concern' Doubt	16-01-12	CI
Regenicin, Inc. announced that it has received $0.075 million in funding	13-12-30	CI
Regenicin, Inc. announced that it has received $0.025 million in funding	13-05-30	CI

Chart Regenicin, Inc.

Duration

Period

More charts

Company Profile

Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENICIN, INC.	+9,900.00%	15.35K
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs